Graphite Bio develops therapies to cure a range of serious and life-threatening diseases. Co.'s gene editing platform is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Co.'s product candidate nulabeglogene autogedtemcel is designed to correct the genetic mutation responsible for sickle cell disease. Co.'s gene replacement approach is designed to allow it to replace dysfunctional genes with a normal copy of an entire gene at its normal location in the chromosome. Co. has two gene replacement programs, one for beta-thalassemia and another for X-linked severe combined immunodeficiency syndrome. The GRPH stock yearly return is shown above.
The yearly return on the GRPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GRPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|